

APPENDIX A

ATSDR MINIMAL RISK LEVEL

The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99–499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological profiles for each substance included on the priority list of hazardous substances; and assure the initiation of a research program to fill identified data needs associated with the substances.

The toxicological profiles include an examination, summary, and interpretation of available toxicological information and epidemiologic evaluations of a hazardous substance. During the development of toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are used by ATSDR health assessors to identify contaminants and potential health effects that may be of concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or action levels.

MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor approach. They are below levels that might cause adverse health effects in the people most sensitive to such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and chronic (365 days and longer) durations and for the oral and inhalation routes of exposure. Currently, MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end point considered to be of relevance to humans. Serious health effects (such as irreparable damage to the liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level above the MRL does not mean that adverse health effects will occur.

APPENDIX A

MRLs are intended only to serve as a screening tool to help public health professionals decide where to look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health principle of prevention. Although human data are preferred, MRLs often must be based on animal studies because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes that humans are more sensitive to the effects of hazardous substance than animals and that certain persons may be particularly sensitive. Thus, the resulting MRL may be as much as a hundredfold below levels that have been shown to be nontoxic in laboratory animals.

Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the Division of Toxicology, expert panel peer reviews, and agencywide MRL Workgroup reviews, with participation from other federal agencies and comments from the public. They are subject to change as new information becomes available concomitant with updating the toxicological profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels. For additional information regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road, Mailstop E-29, Atlanta, Georgia 30333.

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical name: Chlorfenvinphos
CAS number: 470-90-6
Date: August 21, 1996
Profile status: Final
Route: Inhalation Oral
Duration: Acute Intermediate Chronic
Key to figure: 13
Species: Rat

MRL: 0.002 mg/kg/day ppm mg/m³

Reference: Barna J, Simon G. 1973. The effect of chlorfenvinphos insecticide in small often repeated dose. Cereal Research Commun. Vol.1, No. 3: 33-44.

Experimental design (human study details or strain, number of animals per exposure/control group, sex, dose administration details):

Two groups (55/group) of adult female albino (Wistar) rats weighing 208 g were orally administered Birlane[®] (chlorfenvinphos) at dose of 0 or 2.4 mg/kg/day in the diet for 10 days. The study was designed to investigate the effects of oral chlorfenvinphos on body weight increase, the gastrointestinal absorption of glucose, Na⁺, and Ca²⁺, as well as the effects of oral chlorfenvinphos on plasma and erythrocyte cholinesterase activity levels.

Effects noted in study and corresponding doses:

Plasma cholinesterase activity was inhibited by 52% while erythrocyte cholinesterase activity level was inhibited by 30% at a dose of 2.4 mg/kg/day (the only dose tested). Gastrointestinal (g.i.) absorption of glucose was increased by 30% over control values while Na⁺ absorption was decreased by 32% below control values. Gastrointestinal absorption of Ca²⁺ and body weight increases were unaffected by chlorfenvinphos exposure. These changes in the gastrointestinal absorption of glucose and Na⁺ were not considered statistically significant (P>0.05) by the investigators.

Dose endpoint used for MRL derivation:

NOAEL LOAEL

2.4 mg/kg/day; 30% decrease in erythrocyte cholinesterase activity in female rats.

Uncertainty factors used in MRL derivation:

1 3 10 (for use of a LOAEL)
 1 3 10 (for extrapolation from animals to humans)
 1 3 10 (for human variability)

Was a conversion factor used from ppm in food or water to a mg/body weight dose?

If so, explain: No, the doses used are author-provided.

If an inhalation study in animals, list conversion factors used in determining human equivalent dose:

Not applicable.

APPENDIX A

Was a conversion used from intermittent to continuous exposure?

Not applicable.

Other additional studies or pertinent information that lend support to this MRL:

Neurological effects, mediated by cholinesterase inhibition, is the principal and most sensitive toxicological consequence of acute-duration exposure to chlorfenvinphos in humans (Cupp et al. 1975; Pach et al. 1987). Chlorfenvinphos also inhibits noradrenaline in the central nervous system (Brzezinski 1978). Human subjects, exposed to large acute doses of chlorfenvinphos, exhibited severe cholinergic signs. These cholinergic signs were relieved by the administration of atropine and/or pralidoxime, indicating cholinesterase inhibition etiology (Cupp et al. 1975; Pach et al. 1987). In rats, relatively moderate to low doses (2.4–30 mg/kg) of oral chlorfenvinphos significantly inhibited cholinesterase activities in a number of tissue including the brain, erythrocyte, and plasma (Osumi et al. 1975; Osicka-Koprowska et al. 1984; Puzynska 1984). An acute-duration oral study also found alterations in noradrenaline level in rat brain following exposure to chlorfenvinphos. A chlorfenvinphos dose of 13 mg/kg decreased noradrenaline levels in rat brains by 20%, as compared to control rats. According to the investigators, chlorfenvinphos accelerated the rate of NA disappearance from the brain (Brzezinski 1978).

Therefore, it is appropriate to base the acute oral MRL for chlorfenvinphos on cholinesterase inhibition.

It should be noted that a study by Osumi et al. (1975) which determined a NOAEL of 1 mg/kg/day and a LOAEL of 2 mg/kg/day for 38% inhibition of brain cholinesterase in rats was not used to calculate an acute oral MRL because of the gavage (oral) route of administration of the test substance which was deemed less appropriate by the ATSDR MRL Workgroup. An oral feeding study is preferred by the ATSDR MRL Workgroup.

Agency Contact (Chemical Manager): Alfred Dorsey.

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical name: Chlorfenvinphos
CAS number: 470-90-6
Date: August 21, 1996
Profile status: Final
Route: Inhalation Oral
Duration: Acute Intermediate Chronic
Key to figure: 23
Species: Mouse

MRL: 0.002 mg/kg/day ppm mg/m³

Reference: Kowalczyk-Bronisz S, Gieldanowski J, Bubak, Kotz J. 1992. Studies on the effect of pesticide chlorfenvinfos on mouse immune system. *Arc Immunol Ther Exp (Warsz)* 40(5-6):283-289.

Experimental design (human study details or strain, number of animals per exposure/control group, sex, dose administration details):

The authors investigated the effect of chlorfenvinphos on mouse immune system. In the study, male and female inbred C57BL/6 mice and (C57BL/6 x DBA/2)F1 (BDF1/liw) hybrids mice (6-8 weeks old) were orally dosed with chlorfenvinphos (suspended in 1% methylcellulose solution) and evaluated for 5 days for the effect of chlorfenvinphos exposure on the mouse immune system. The rats were exposed to oral chlorfenvinphos doses of 0, 1.5, 3, and 6 mg/kg (0, 1/100, 1/50, and 1/25 LD₅₀) daily for 3 months; control group was given 1% methylcellulose. Then exposed and control mice were immunized by intraperitoneal injections of 0.2 mL 10% SRBC. IgM-PFC (plaque-forming or antibody-producing cells) number in spleen cell suspension was tested on day 4 after immunization and the procedure repeated 3 weeks after the exposure to chlorfenvinphos had been ceased. Exposed and control groups were subjected to immunological tests and hematological examinations. Lymphatic organs were histologically examined.

Effects noted in study and corresponding doses:

A dose-related decrease in number of hemolysin producing cells was observed: plaque-forming cells (PFC) were 58% at the 6 mg/kg dose group and 85% at the 3 mg/kg dose level as compared to control values. Chlorfenvinphos treatment also caused reduction in E rosettes forming cell number by 30% at the 6 mg/kg dose level and by 25% at the 3 mg/kg dose level. Increases in Interlukin-1 (IL-1) activity and DTH reaction were observed 24 hours after challenge. Spleen colonies were stimulated as evidenced by the increase of endogenous spleen colonies and exogenous spleen colonies (CFU-S) increased 190% at the 1.48 mg/kg dose level and 137% at the 6 mg/kg dose level, and 162% at 1.5 mg/kg dose level and 70% at the 6 mg/kg dose level, respectively). When the IgM PFC number was tested 3 weeks latter, after the exposure to chlorfenvinphos in the small dose (1.5 mg/kg), and increase (about 40%) in plaques number was observed. There was a 50% reduction in thymus weight at the 1.5 mg/kg dose level as compared to controls as well as significant involution of thymus was noted.

Dose endpoint used for MRL derivation:

NOAEL LOAEL

APPENDIX A

1.5 mg/kg/day; 190% increase of spleen endogenous colonies; 162% increase of spleen exogenous colonies; 50% reduction in thymus weight.

Uncertainty factors used in MRL derivation:

- 1 3 10 (for use of a LOAEL)
- 1 3 10 (for extrapolation from animals to humans)
- 1 3 10 (for human variability)

Was a conversion factor used from ppm in food or water to a mg/body weight dose?

If so, explain: Doses were provided as 1/100, 1/50, and 1/25 of the LD₅₀ (148 mg/kg) by the authors, resulting in doses of 1.5, 3, and 6 mg/kg, respectively.

If an inhalation study in animals, list conversion factors used in determining human equivalent dose:

Not applicable.

Was a conversion used from intermittent to continuous exposure?

Not applicable.

Other additional studies or pertinent information that lend support to this MRL:

In other studies, adverse immunolymphoreticular effects has been associated with exposure to oral chlorfenvinphos. In an intermediate-duration dietary study with albino (Wistar) rats, there was a significant and irreversible reduction in relative spleen weight of female rats given 3 mg/kg/day chlorfenvinphos for 12 weeks (Ambrose et al. 1970). A study was undertaken to evaluate selected serological and cytoimmunological reactions in rabbits subjected to a long-term poisoning with subtoxic oral doses (10 mg/kg in a soya oil solution with a small amount of food) of chlorfenvinphos for 90 days. Chlorfenvinphos treatment significantly elevated serum hemagglutinin level (16%) and hemolysin activity (66%, P<0.05) as well as increased the number of nucleated lymphoid cells producing hemolytic antibody to sheep erythrocytes as compared to controls (treated 906, P<0.05 and controls 618). Spleen cytomorphology changes, manifested mainly as transformation of primary follicles into secondary ones with well developed germinal centers, were also observed (Roszkowski 1978).

Therefore, it is appropriate to base the intermediate oral MRL for chlorfenvinphos on immunological effects.

Agency Contact (Chemical Manager): Alfred Dorsey.

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical name: Chlorfenvinphos
CAS number: 470-90-6
Date: August 21, 1996
Profile status: Final
Route: Inhalation Oral
Duration: Acute Intermediate Chronic
Key to figure: 34
Species: Rat

MRL: 0.0007 mg/kg/day ppm mg/m³

Reference: Ambrose AM, Larson PS, Borzelleca JF, Hennigar GR. 1970. Toxicologic studies on diethyl-1-(2,4-dichlorophenyl)-2-chlorovinyl phosphate. Toxicology and Applied Pharmacology, 17:323-336.

Experimental design (human study details or strain, number of animals per exposure/control group, sex, dose administration details):

The authors conducted toxicological studies with chlorfenvinphos in weaning albino (Wistar) rats. In the study, four matched groups of weaning albino (Wistar) rats (30 rats/sex/group) were culled to a narrow starting weight range and fed daily GC-4072 (technical chlorfenvinphos) doses of 0, 0.7, 2.1, 7, or 21 mg/kg/day (males) or 0, 0.8, 2.4, or 8, or 24 mg/kg/day (females) in the diet for 104 weeks. An additional group of non-littermate rats (30/sex) were administered 21 mg/kg/day (males) or 24 mg/kg/day (females) chlorfenvinphos for 104 weeks. Plasma and erythrocyte cholinesterase (ChE) activity levels were obtained from 4 rats of each sex per dose group at 1, 4, 8, and 12 weeks. At 13 weeks, 4 rats/sex/dose group were sacrificed for histopathologic examination. At 13 weeks, 4 rats/sex/dose group were sacrificed for histopathologic examination. The rats in the 21 mg/kg/day (males) and 24 mg/kg/day (females) were sacrificed on the 95th week while all other dose group animals were sacrificed on the end of the study (104 weeks). At each autopsy, relative organ weights were determined for heart and kidneys. All animals sacrificed in moribund condition as well as those sacrificed at week 13, 95, and 104 weeks were examined grossly and microscopically and organs (heart, lungs, liver, kidney, urinary bladder, spleen, stomach, small and large intestine, skeletal muscle, skin, bone marrow, pancreas, thyroid, adrenal, pituitary) from these animals were histopathologically examined. Chlorfenvinphos significantly decreased body weight gain of females at the 8 and 24 mg/kg/day dose groups from the 26th week till towards the end of the study, although, the decreased body weight gain became not statistically significant at the end of the study. Increased relative liver weights were observed in males at the 7 mg/kg/day dose level but no other signs of hepatopathology was reported. No consistent difference in body weight gains in males, survival of the test animals, food consumption, or mortality was evident at all dose levels tested, as compared to undosed controls. Essentially, no gross or microscopic histopathology were evident in all the organs (heart, lungs, liver, kidney, urinary bladder, spleen, stomach, small and large intestine, skeletal muscle, skin, bone marrow, pancreas, thyroid, adrenal, pituitary) tissues examined. No changes in organ-to-body weight were observed in the heart, kidney, spleen and testes (Ambrose et al. 1970).

Dose endpoint used for MRL derivation:

NOAEL LOAEL

APPENDIX A

0.7 mg/kg/day; 45% inhibition of plasma cholinesterase activity; 33% inhibition of erythrocyte cholinesterase activity

Uncertainty factors used in MRL derivation:

- 1 3 10 (for use of a LOAEL)
 1 3 10 (for extrapolation from animals to humans)
 1 3 10 (for human variability)

Was a conversion factor used from ppm in food or water to a mg/body weight dose?

If so, explain: Doses, provided as food concentrations (10, 30, 100, or 300 ppm), were converted to doses in mg/kg/day using rat daily food intake factor for chronic Wistar rat obtained from EPA (1988).

CALCULATIONS: 10 ppm = 10 mg/kg; Male - 10 mg/kg x 0.07 mg/kg/day (chronic male Wistar rat food factor) = 0.7 mg/kg/day; 30 ppm = 2.1 mg/kg/day; 100 ppm = 7 mg/kg/day; 300 ppm = 21 mg/kg/day; Female - 10 mg/kg x 0.08 mg/kg/day (chronic female Wistar rat food factor) = 0.8 mg/kg/day; 30 ppm = 2.4 mg/kg/day; 100 ppm = 7 mg/kg/day; 300 ppm = 24 mg/kg/day.

If an inhalation study in animals, list conversion factors used in determining human equivalent dose:

Not applicable.

Was a conversion used from intermittent to continuous exposure? Not applicable.

Other additional studies or pertinent information that lend support to this MRL:

Although the neurological effects of human prolonged exposure to low oral doses of chlorfenvinphos is not known due to a dearth of studies, acute-duration exposure data indicate that neurological effects, mediated by cholinesterase inhibition, is the most sensitive toxicological consequence of human exposure to chlorfenvinphos (Cupp et al. 1975; Pach et al. 1987; Taitelman 1992). Similarly, chlorfenvinphos significantly inhibited both plasma and erythrocyte cholinesterase activities in Beagle dogs (2/sex) fed daily chlorfenvinphos doses of 0, 0.3, 2, or 10 mg/kg/day (males), or 0, 1.5, 10, or 50 mg/kg/day (females) in the diet (moist) for 104 weeks. Plasma cholinesterase activities were significantly inhibited at all dietary levels through week 39 of the study; 49% inhibition at the 0.3 mg/kg/day (males) and 1.5 mg/kg/day (females) dose levels. Erythrocyte cholinesterase activity was significantly and consistently inhibited (36%) during the first 12 weeks only in the 10 mg/kg/day (males) and 50 mg/kg/day (females) dose levels (Ambrose et al. 1970).

Therefore, it is considered appropriate to use this endpoint for developing a chronic oral MRL for chlorfenvinphos.

Agency Contact (Chemical Manager): Alfred Dorsey.

APPENDIX B

USER'S GUIDE

Chapter 1

Public Health Statement

This chapter of the profile is a health effects summary written in non-technical language. Its intended audience is the general public especially people living in the vicinity of a hazardous waste site or chemical release. If the Public Health Statement were removed from the rest of the document, it would still communicate to the lay public essential information about the chemical.

The major headings in the Public Health Statement are useful to find specific topics of concern. The topics are written in a question and answer format. The answer to each question includes a sentence that will direct the reader to chapters in the profile that will provide more information on the given topic.

Chapter 2

Tables and Figures for Levels of Significant Exposure (LSE)

Tables (2-1, 2-2, and 2-3) and figures (2-1 and 2-2) are used to summarize health effects and illustrate graphically levels of exposure associated with those effects. These levels cover health effects observed at increasing dose concentrations and durations, differences in response by species, minimal risk levels (MRLs) to humans for noncancer endpoints, and EPA's estimated range associated with an upper-bound individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to locate data for a specific exposure scenario. The LSE tables and figures should always be used in conjunction with the text. All entries in these tables and figures represent studies that provide reliable, quantitative estimates of No-Observed-Adverse-Effect Levels (NOAELs), Lowest-Observed-Adverse-Effect Levels (LOAELs), or Cancer Effect Levels (CELs).

The legends presented below demonstrate the application of these tables and figures. Representative examples of LSE Table 2-1 and Figure 2-1 are shown. The numbers in the left column of the legends correspond to the numbers in the example table and figure.

LEGEND

See LSE Table 2-1

- (1) Route of Exposure One of the first considerations when reviewing the toxicity of a substance using these tables and figures should be the relevant and appropriate route of exposure. When sufficient data exists, three LSE tables and two LSE figures are presented in the document. The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE Table 2-1, 2-2, and 2-3, respectively). LSE figures are limited to the inhalation (LSE Figure 2-1) and oral (LSE Figure 2-2) routes. Not all substances will have data on each route of exposure and will not therefore have all five of the tables and figures.
- (2) Exposure Period Three exposure periods - acute (less than 15 days), intermediate (15–364 days), and chronic (365 days or more) are presented within each relevant route of exposure. In this example, an inhalation study of intermediate exposure duration is reported. For quick reference to health effects occurring from a known length of exposure, locate the applicable exposure period within the LSE table and figure.

APPENDIX B

- (3) Health Effect The major categories of health effects included in LSE tables and figures are death, systemic, immunological, neurological, developmental, reproductive, and cancer. NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. Systemic effects are further defined in the "System" column of the LSE table (see key number 18).
- (4) Key to Figure Each key number in the LSE table links study information to one or more data points using the same key number in the corresponding LSE figure. In this example, the study represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL (also see the 2 "18r" data points in Figure 2-1).
- (5) Species The test species, whether animal or human, are identified in this column. Section 2.5, "Relevance to Public Health," covers the relevance of animal data to human toxicity and Section 2.3, "Toxicokinetics," contains any available information on comparative toxicokinetics. Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent human doses to derive an MRL.
- (6) Exposure Frequency/Duration The duration of the study and the weekly and daily exposure regimen are provided in this column. This permits comparison of NOAELs and LOAELs from different studies. In this case (key number 18), rats were exposed to toxaphene via inhalation for 6 hours per day, 5 days per week, for 3 weeks. For a more complete review of the dosing regimen refer to the appropriate sections of the text or the original reference paper, i.e., Nitschke et al. 1981.
- (7) System This column further defines the systemic effects. These systems include: respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems. In the example of key number 18, 1 systemic effect (respiratory) was investigated.
- (8) NOAEL A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure level at which no harmful effects were seen in the organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see footnote "b").
- (9) LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest dose used in the study that caused a harmful health effect. LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help readers identify the levels of exposure at which adverse health effects first appear and the gradation of effects with increasing dose. A brief description of the specific endpoint used to quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key number 18 (hyperplasia) is a Less serious LOAEL of 10 ppm. MRLs are not derived from Serious LOAELs.
- (10) Reference The complete reference citation is given in Chapter 8 of the profile.
- (11) CEL A Cancer Effect Level (CEL) is the lowest exposure level associated with the onset of carcinogenesis in experimental or epidemiologic studies. CELs are always considered serious effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report doses not causing measurable cancer increases.
- (12) Footnotes Explanations of abbreviations or reference notes for data in the LSE tables are found in the footnotes. Footnote "b" indicates the NOAEL of 3 ppm in key number 18 was used to derive an MRL of 0.005 ppm.

APPENDIX B

LEGEND**See Figure 2-1**

LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the reader quickly compare health effects according to exposure concentrations for particular exposure periods.

- (13) Exposure Period The same exposure periods appear as in the LSE table. In this example, health effects observed within the intermediate and chronic exposure periods are illustrated.
- (14) Health Effect These are the categories of health effects for which reliable quantitative data exists. The same health effects appear in the LSE table.
- (15) Levels of Exposure concentrations or doses for each health effect in the LSE tables are graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log scale "y" axis. Inhalation exposure is reported in mg/m³ or ppm and oral exposure is reported in mg/kg/day.
- (16) NOAEL In this example, 18r NOAEL is the critical endpoint for which an intermediate inhalation exposure MRL is based. As you can see from the LSE figure key, the open-circle symbol indicates to a NOAEL for the test species-rat. The key number 18 corresponds to the entry in the LSE table. The dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see entry 18 in the Table) to the MRL of 0.005 ppm (see footnote "b" in the LSE table).
- (17) CEL Key number 38r is 1 of 3 studies for which Cancer Effect Levels were derived. The diamond symbol refers to a Cancer Effect Level for the test species-mouse. The number 38 corresponds to the entry in the LSE table.
- (18) Estimated Upper-Bound Human Cancer Risk Levels This is the range associated with the upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the cancer dose response curve at low dose levels (q_1^*).
- (19) Key to LSE Figure The Key explains the abbreviations and symbols used in the figure.

SAMPLE

1⁶

TABLE 2-1. Levels of Significant Exposure to [Chemical x] – Inhalation

2⁶

3⁶

4⁶

Key to figure ^a	Species	Exposure frequency/duration	System	NOAEL (ppm)	LOAEL (effect)		Reference
					Less serious (ppm)	Serious (ppm)	
INTERMEDIATE EXPOSURE							
	5	6	7	8	9		10
Systemic	9	9	9	9	9		9
18	Rat	13 wk 5d/wk 6hr/d	Resp	3 ^b	10 (hyperplasia)		Nitschke et al. 1981
CHRONIC EXPOSURE							
						11	
Cancer						9	
38	Rat	18 mo 5d/wk 7hr/d				20	(CEL, multiple organs) Wong et al. 1982
39	Rat	89–104 wk 5d/wk 6hr/d				10	(CEL, lung tumors, nasal tumors) NTP 1982
40	Mouse	79–103 wk 5d/wk 6hr/d				10	(CEL, lung tumors, hemangiosarcomas) NTP 1982

12⁶


^a The number corresponds to entries in Figure 2-1.

^b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5×10^{-3} ppm; dose adjusted for intermittent exposure and divided by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).

CEL = cancer effect level; d = days(s); hr = hour(s); LOAEL = lowest-observed-adverse-effect level; mo = month(s); NOAEL = no-observed-adverse-effect level; Resp = respiratory; wk = week(s)

SAMPLE

13 → Figure 2-1. Levels of Significant Exposure to [Chemical X] – Inhalation



APPENDIX B

Chapter 2 (Section 2.5)**Relevance to Public Health**

The Relevance to Public Health section provides a health effects summary based on evaluations of existing toxicologic, epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, weight-of-evidence discussions for human health endpoints by addressing the following questions.

1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous waste sites?

The section covers endpoints in the same order they appear within the Discussion of Health Effects by Route of Exposure section, by route (inhalation, oral, dermal) and within route by effect. Human data are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). *In vitro* data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered in this section. If data are located in the scientific literature, a table of genotoxicity information is included.

The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer potency or perform cancer risk assessments. Minimal risk levels (MRLs) for noncancer endpoints (if derived) and the endpoints from which they were derived are indicated and discussed.

Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public health are identified in the Data Needs section.

Interpretation of Minimal Risk Levels

Where sufficient toxicologic information is available, we have derived minimal risk levels (MRLs) for inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not meant to support regulatory action; but to acquaint health professionals with exposure levels at which adverse health effects are not expected to occur in humans. They should help physicians and public health officials determine the safety of a community living near a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water. MRLs are based largely on toxicological studies in animals and on reports of human occupational exposure.

MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2.5, "Relevance to Public Health," contains basic information known about the substance. Other sections such as 2.7, "Interactions with Other Substances," and 2.8, "Populations that are Unusually Susceptible" provide important supplemental information.

MRL users should also understand the MRL derivation methodology. MRLs are derived using a modified version of the risk assessment methodology the Environmental Protection Agency (EPA) provides (Barnes and Dourson 1988) to determine reference doses for lifetime exposure (RfDs).

To derive an MRL, ATSDR generally selects the most sensitive endpoint which, in its best judgement, represents the most sensitive human health effect for a given exposure route and duration. ATSDR cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available for all potential systemic, neurological, and developmental effects. If this information and reliable quantitative data on the chosen endpoint are available, ATSDR derives an MRL using the most sensitive species (when information from

APPENDIX B

multiple species is available) with the highest NOAEL that does not exceed any adverse effect levels. When a NOAEL is not available, a lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor (UF) of 10 must be employed. Additional uncertainty factors of 10 must be used both for human variability to protect sensitive subpopulations (people who are most susceptible to the health effects caused by the substance) and for interspecies variability (extrapolation from animals to humans). In deriving an MRL, these individual uncertainty factors are multiplied together. The product is then divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used in developing a substance-specific MRL are provided in the footnotes of the LSE Tables.

APPENDIX C

ACRONYMS, ABBREVIATIONS, AND SYMBOLS

ACGIH	American Conference of Governmental Industrial Hygienists
ADME	Absorption, Distribution, Metabolism, and Excretion
atm	atmosphere
ATSDR	Agency for Toxic Substances and Disease Registry
BCF	bioconcentration factor
BSC	Board of Scientific Counselors
C	Centigrade
CDC	Centers for Disease Control
CEL	Cancer Effect Level
CERCLA	Comprehensive Environmental Response, Compensation, and Liability Act
CFR	Code of Federal Regulations
CLP	Contract Laboratory Program
cm	centimeter
CNS	central nervous system
d	day
DHEW	Department of Health, Education, and Welfare
DHHS	Department of Health and Human Services
DOL	Department of Labor
ECG	electrocardiogram
EEG	electroencephalogram
EPA	Environmental Protection Agency
EKG	see ECG
F	Fahrenheit
F ₁	first filial generation
FAO	Food and Agricultural Organization of the United Nations
FEMA	Federal Emergency Management Agency
FIFRA	Federal Insecticide, Fungicide, and Rodenticide Act
fpm	feet per minute
ft	foot
FR	<i>Federal Register</i>
g	gram
GC	gas chromatography
gen	generation
HPLC	high-performance liquid chromatography
hr	hour
IDLH	Immediately Dangerous to Life and Health
IARC	International Agency for Research on Cancer
ILO	International Labor Organization
in	inch
K _d	adsorption ratio
kg	kilogram
kkg	metric ton
K _{oc}	organic carbon partition coefficient
K _{ow}	octanol-water partition coefficient
L	liter
LC	liquid chromatography
LC _{Lo}	lethal concentration, low
LC ₅₀	lethal concentration, 50% kill

APPENDIX C

LD _{Lo}	lethal dose, low
LD ₅₀	lethal dose, 50% kill
LOAEL	lowest-observed-adverse-effect level
LSE	Levels of Significant Exposure
m	meter
mg	milligram
min	minute
mL	milliliter
mm	millimeter
mm Hg	millimeters of mercury
mmol	millimole
mo	month
mppcf	millions of particles per cubic foot
MRL	Minimal Risk Level
MS	mass spectrometry
NIEHS	National Institute of Environmental Health Sciences
NIOSH	National Institute for Occupational Safety and Health
NIOSHTIC	NIOSH's Computerized Information Retrieval System
ng	nanogram
nm	nanometer
NHANES	National Health and Nutrition Examination Survey
nmol	nanomole
NOAEL	no-observed-adverse-effect level
NOES	National Occupational Exposure Survey
NOHS	National Occupational Hazard Survey
NPL	National Priorities List
NRC	National Research Council
NTIS	National Technical Information Service
NTP	National Toxicology Program
OSHA	Occupational Safety and Health Administration
PEL	permissible exposure limit
pg	picogram
pmol	picomole
PHS	Public Health Service
PMR	proportionate mortality ratio
ppb	parts per billion
ppm	parts per million
ppt	parts per trillion
REL	recommended exposure limit
RfD	Reference Dose
RTECS	Registry of Toxic Effects of Chemical Substances
sec	second
SCE	sister chromatid exchange
SIC	Standard Industrial Classification
SMR	standard mortality ratio
STEL	short term exposure limit
STORET	STORAGE and RETRIEVAL
TLV	threshold limit value
TSCA	Toxic Substances Control Act
TRI	Toxics Release Inventory
TWA	time-weighted average
U.S.	United States
UF	uncertainty factor

APPENDIX C

yr	year
WHO	World Health Organization
wk	week
>	greater than
≥	greater than or equal to
=	equal to
<	less than
≤	less than or equal to
%	percent
α	alpha
β	beta
δ	delta
γ	gamma
μm	micrometer
μg	microgram